



Harnessing the power of T cell measurement

Press Release

At Oxford Immunotec: Dr Peter Wrighton-Smith, CEO Tel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email: info@oxfordimmunotec.com	Oxford Immunotec 94c Milton Park Abingdon Oxfordshire OX14 4RY, UK	Oxford Immunotec Inc, 2 Mount Royal Avenue, Marlborough, MA 01752
--	---	--

STUDY RESULTS CONFIRM T-SPOT[®].TB PERFORMANCE IS NOT AFFECTED BY LOW CD4 COUNT IN HIV INFECTED SUBJECTS

Oxford, UK; 23 May 2008 – Oxford Immunotec, the T cell measurement company, today announced the publication of a recent study, demonstrating the efficacy of using T-SPOT.TB to identify TB infection in HIV infected subjects.

In this study reported in *Clinical and Experimental Immunology* Clark *et al* showed that the T-SPOT.TB test was unaffected by CD4 count, having the same high sensitivity in patients with a very low CD4 count (less than 100 cells/ μ l) as those with a more normal CD4 count (above 400 cells/ μ l).

In the publication the authors conclude that “T-SPOT.TB is a useful assay to screen for TB infection even in HIV-1 patients with low CD4 counts and can be used in routine clinical practice”.

Commenting on the results, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “this study confirms the role of T-SPOT.TB in the identification of TB infection in HIV infected subjects. This is particularly important as TB is one of the major causes of death in HIV infected subjects and the rates of TB/HIV co-infection are reaching epidemic proportions in some populations”.

– Ends –

Notes to editors:

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec, the T cell measurement company is based in Oxford, UK and Marlborough, MA. The Company develops and sells clinical diagnostic products based on its patented T-SPOT[®] technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person's cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT[®].TB

T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market opportunity exceeding \$1bn.

T-SPOT[®] is a trademark of Oxford Immunotec.

Journal Reference

Clark S, Martin S, Pozniak A, Steel A, Ward B, Dunning J, Henderson D, Nelson M, Gazzard B and Kelleher P. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. *Clinical and Experimental Immunology*. 1365-2249. 2007.